This study by Bove et al. (Multiple Sclerosis, 2017) evaluated the relationship between oral contraceptives (OCs) and risk of relapse for women with multiple sclerosis (MS).
Longitudinal observational cohort study
162 women with MS or clinically isolated syndrome (CIS) taking OCs who had begun injectable disease-modifying therapy within two years of diagnoses were studied. The study examined women who currently take OCs, had taken OCs in the past, and those who had never taken OCs. Women who had previously taken OCs had lower rates of relapse than those who had never take OCs. Annualized relapse rate was not significantly different across the three groups of women. Important conclusion based on the data – OC use does not increase risk of MS relapse.
Oral contraceptives and MS disease activity in a contemporary real-world cohort
Please login to access ObGFirst and the T2 US Atlas
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
